Mode
Text Size
Log in / Sign up

Systematic review synthesizes immune and genetic factors in African SARS-CoV-2 populations

Systematic review synthesizes immune and genetic factors in African SARS-CoV-2 populations
Photo by National Cancer Institute / Unsplash
Key Takeaway
Note heterogeneity in African SARS-CoV-2 studies limits definitive clinical application for individual management.

This publication is a narrative synthesis that reviews 40 studies conducted in African settings concerning SARS-CoV-2 infection. The scope encompasses immune responses, cytokine profiles, and genetic associations within these populations. The authors do not report specific adverse events or trial-level safety data.

Key synthesized findings indicate widespread pre-existing immunity, including cross-reactive antibodies and polyfunctional T-cell responses. Cytokine profiles vary by severity, with elevated IL-6, TNF-α, and IFN-γ observed in severe cases, while asymptomatic individuals show broader, milder profiles. Antibody responses are described as robust across disease severities with long-lasting IgG activity. Genetic analysis identifies specific risk alleles, such as HLA-B41, B42, C16, and C17, alongside protective alleles including HLA-DQB106, DQB103, and B*15. ACE2 polymorphisms rs2285666 and rs73635825 are reportedly prevalent and linked to varied ACE2 expression, viral load, and disease severity.

The authors acknowledge significant limitations, noting heterogeneity in study designs and outcomes. This heterogeneity affects the certainty of the pooled observations and prevents definitive causal conclusions. No specific funding conflicts or discontinuations were reported in the source material.

The practice relevance of this review lies in shaping future public health responses. Clinicians should interpret these genetic and immunological patterns as descriptive associations rather than established causal mechanisms for individual patient management. The lack of reported adverse events and specific effect sizes limits direct clinical application for prescribing or risk stratification at this stage.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had immense global consequences, leading to widespread illness, deaths, and devastated economies. Despite this, Africa has experienced a high prevalence of asymptomatic coronavirus disease 2019 (COVID-19) and mild cases. While reported cases and deaths have been lower, limited testing and undiagnosed infections make it difficult to determine the true burden of the disease. Understanding the unique immune response and the variations in genetics affect COVID-19 outcomes in African populations is important for shaping future public health responses. This review examines key immune factors and genetic variations in key host proteins that may help explain why COVID-19 was less severe in Africa.MethodologyA systematic review was conducted following PRISMA guidelines to identify studies published between 2019 and January 2026 that investigated immunological responses and genetic variations associated with COVID-19 in African populations. Literature searches were performed in PubMed, Scopus, and African Journals Online (AJOL). Inclusion criteria focused on studies reporting responses from cytokines, T-cells, antibodies or host genetic factors. After screening 4,170 records and removing duplicates, 420 studies were assessed for abstracts, and 240 full texts were reviewed. A total of 40 studies were included, and data synthesized narratively due to heterogeneity in study designs and outcomes.ResultsOf the 40 studies analyzed from 19 African populations, 26 focused on immunological responses and 9 on host genetic factors. Immune studies revealed widespread pre-existing immunity, including cross-reactive antibodies (especially to the N proteins) and polyfunctional T-cell responses, likely shaped by exposure to malaria, helminths, and other coronaviruses. Severe COVID-19 cases showed elevated IL-6, TNF-α, and IFN-γ, while asymptomatic individuals had broader, milder cytokine profiles. Antibody responses were robust across disease severities, with long-lasting IgG activity. Genetic studies identified HLA-B41, B42, C16, and C17 as risk alleles, while HLA-DQB106, DQB103, and B*15 conferred protection. ACE2 polymorphisms including rs2285666, rs73635825 were reportedly prevalent in Africans and were linked to varied ACE2 expression, viral load, and disease severity.ConclusionThe findings suggest that immune and genetic adaptations in African populations may have modulated susceptibility and severity of SARS-CoV-2 infection outcomes in Africans.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view, identifier CRD420251121731.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.